AbbVie completes $10.0 billion notes offering to help fund Apogee acquisition
AbbVie completed an underwritten offering of nine series of senior notes on August 18, 2026, totaling $10.0 billion in principal across floating rate notes maturing 2028 and fixed rate notes maturing 2028 through 2066. AbbVie expects to use the net proceeds to fund part of the cash consideration for its acquisition of Apogee Therapeutics and related fees, with any remainder for general corporate purposes.
Key points
- Nine series of notes totaling $10.0 billion in aggregate principal, registered under AbbVie's Form S-3ASR dated February 14, 2025
- Net proceeds to fund a portion of the cash consideration due to Apogee shareholders and related fees and expenses
- If the Apogee acquisition is terminated or abandoned, AbbVie must redeem most series (not the 2056 or 2066 Notes) at 101% of principal plus accrued interest
- Notes are unsecured and rank equally with AbbVie's existing and future unsecured, unsubordinated debt
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.